Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

Now Viewing

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Compared with BCMA-directed therapies, talquetamab shows less pronounced infection risk, likely due to the continuous dosing of bispecific antibodies that constantly challenges the immune system vs the transient effects of chimeric antigen receptor T-cell therapy. However, talquetamab’s targeting of GPRC5D expressed on gastrointestinal and skin tissues causes unique toxicities such as dysgeusia, dermatologic changes, and nail abnormalities. Compared with grade 3 or higher infection rates of 40% or more with BCMA therapies, grade 3 or higher infection rates areless than 20% with talquetamab. Other distinctive toxicities may include hair changes and testicular effects, though manifestations are unclear. Overall, talquetamab demonstrates efficacy comparability to BCMA-directed treatments but a differentiated safety profile.

Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.